[ad_1]
João Gabbardo, executive coordinator of the São Paulo Coronavirus Contingency Center, criticized today a speech by President Jair Bolsonaro (without a party), who affirmed that he will send a team to Israel to learn about the EXO-CD24 nasal spray, a drug. that began to be tested against COVID-19 only recently in that country and still does not have published efficacy data.
“It is incomprehensible to send a group of people to Israel. They should go see what they did in the vaccination and bring positive things. Israel is vaccinating everyone, the number of hospitalizations has dropped sharply and the number of deaths as well. So they go there. To look at something that is being evaluated that has not even gone through phase 1, 2 or 3?
Are you going to Israel to find a magical alternative? It is a totally wrong move by the government.
João Gabbardo, Executive Coordinator of the São Paulo Coronavirus Contingency Center
The statement was given in the UOL interview, made by columnists of the Twitter Carla Araújo and Maria Carolina Trevisan.
Gabbardo also noted that the spray is being tested in severe cases of Covid-19. “Again, are we going to let the population get sick to go to the hospitals?”
Anteontem, Bolsonaro also commented that “it is all right, but I do not want to say what will happen”, so that it is given at the entrance of the documentation of the remedy in test at Anvisa (National Sanitary Surveillance Agency) so that phase 3 of the study will be valid. in Brazil.
What is the spray?
Seen as Bolsonaro’s “new chloroquine”, in reference to the drug already ruled out by the WHO (World Health Organization) to combat the coronavirus, the spray was unveiled after academics from the Tel Aviv Hospital Center reported that the medication was approved in the first days. tests performed. It is, however, a preliminary study in the probing phase applied to the disease, without comparing it with a placebo, for example.
As it was an experiment, the ages of the volunteers and their health problems were not specified. According to the international database of clinical trials, the first phase of the tests began in September and will be completed by the end of this month.
Last week, the Israeli responsible for developing the new product, Nadir Arber of Israel’s Ichilov Hospital, told UOL columnist Jamil Chad that the drug is not ready for use and needs further testing.
According to the director of the Infectious Diseases Society of the Federal District, Lívia Vanessa, “there is no scientific proof of immunization with this nasal spray, not even of treatment for the infection by SARS-CoV2”.
“Randomized, controlled, double-blind clinical trials are needed to determine efficacy and not just isolated case reports,” he said. The doctor also said that in vitro efficacy studies and animal tests are not enough to validate treatment in humans.
Toward Twitter Anvisa (National Health Surveillance Agency) reported, through its notice, that “there is still no request for analysis of use or approval of a clinical study of this drug” – last month, Bolsonaro used social networks to announce that he will send he asked the agency for an emergency release of the drug and made a live broadcast on Facebook defending the drug.
[ad_2]
